New CRISPR element regulates viral defense
Mechanism for prioritizing the immune response discovered
What tasks need to be done today, and which is the most urgent? People have to constantly set priorities in their daily life. Bacteria are no different: They too must prioritize when combating viruses with CRISPR. However, it was unclear how this prioritization takes place. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a joint venture of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University (JMU) Würzburg, in cooperation with researchers from the universities of Würzburg, Freiburg and Leipzig, have now described an underlying mechanism for the first time. Their study was published in the journal Nature Microbiology.
Most bacteria use CRISPR-Cas systems to protect themselves against infecting viruses. The defense systems target snippets of viral DNA and store them between fixed, repeating sequences. These segments, consisting of alternating repeats and snippets of viral DNA, then produce CRISPR ribonucleic acids (RNA). The CRISPR RNAs help the system to recognize and combat viruses. Picking up a viral DNA snippet provides immediate protection. By storing the snippets within the bacterial DNA, protection can be passed on to new generations.
Preventing system overload – but how?
However, the storing process is not without risk: With tens or even hundreds of snippets, probing for that many viruses at one time would overwhelm the CRISPR-Cas systems. As a result, the systems have devised a way to prioritize the newest snippets for defense. This way, they provide stronger protection against the viruses most recently encountered by the cell. While this phenomenon has been known, the underlying mechanism has remained a mystery.
Using the CRISPR-Cas9 system from the pathogen Streptococcus pyogenes as a model, the research team has now discovered that the leader RNA prioritizes immune defense. This sequence is located adjacent to the segment of repeats and viral DNA and is responsible for picking up the viral snippets. During transcription, it folds with the first two repeats surrounding the newest snippet, driving production of the first CRISPR RNA over other CRISPR RNAs. Thus, the system prepares to search for this virus. “The mechanism is specific to many CRISPR systems involving the Cas9 protein commonly used for genome editing, although other mechanisms likely exist for prioritizing anti-viral defense,” says Chunyu Liao, lead author of the study published in the journal Nature Microbiology and former HIRI postdoc.
New CRISPR element, new possibilities
“This outcome was fully unexpected. The leader RNA was only thought to direct where new viral snippets were integrated,” explains corresponding author of the study, Chase Beisel. Beisel is a professor at JMU and head of the Synthetic RNA Biology Department at HIRI.
“The structure formed between this sequence and the first two repeats is a new element in CRISPR biology. It reveals another mechanism by which RNA can contribute to immune defense. Our research assigns a whole new role to the leader sequence, which has not previously been associated with CRISPR RNA production,” adds Liao. According to Beisel, the findings are significant: “The 2020 Nobel Prize in Chemistry was awarded, among other things, for the discovery of how CRISPR systems involving Cas9 produce CRISPR RNAs. Our study offers new insights into this process: It shows why the location of these snippets is as important as their sequence.”
Beyond providing insights into the arms race between bacteria and viruses, this newly discovered mechanism could be used to develop multiplexed CRISPR technologies for the treatment of diseases, which are caused by a variety of mutations in the genome.
This press release is also available on our homepage: https://www.helmholtz-hzi.de/en/news-events/news/view/article/complete/neues-crispr-element-steuert-virenabwehr/
Helmholtz Centre for Infection Research:
Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defence mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases. www.helmholtz-hzi.de/en
The Helmholtz Institute for RNA-based Infection Research:
The Helmholtz Institute for RNA-based Infection Research (HIRI) was founded in May 2017. It is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius-Maximilians-Universität Würzburg (JMU). Based on the University hospital campus, the HIRI is the first federal institute to focus on the role of ribonucleic acids (RNAs) in infection processes. Its mission is to combine basic research with the development of new RNA-centric therapeutic approaches to treat infections. www.helmholtz-hiri.de
Dr. Britta Grigull
Presse & Public Relations
Spacer prioritization in CRISPR-Cas9 immunity is enabled by the leader RNA. Liao C, Sharma S, Svensson SL, Kibe A, Weinberg Z, Alkhnbashi OS, Bischler T, Backofen R, Caliskan N, Sharma CM, Beisel CL (2022). Nature Microbiology, DOI: 10.1038/s41564-022-01074-3